PASSION FOR IDEAS

BIND Biosciences

Bind Biosciences (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010.

BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nanoparticles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).


Recent News

June 29, 2010
BIND Biosciences Secures $12.4 Million Financing
 


Company Info
 
Country: USA
Industry:    LS
Sector: biotechnology
Status: Unrealized
Vehicle: Endeavour II LP


Key persons
 Scott Minick, CEO; Dr. Robert Langer, co-founder; Dr. Omid Farokhzad, co-founder


Company website
 www.bindbio.com


Endeavour Vision Team
 
Olivier Valdenaire
Sven Lingjaerde
partner of the European Tech Tour "The partners have been very supportive of our approach and stepped in to add value when needed. I would strongly recommend them as investors."
Didier Cowling, Founder and CEO, Kuros Biosurgery AG